New York A 1321: Requires passengers to use seatbelts in stretch limousines

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A01321 Summary:

BILL NOA01321 

&nbsp

SAME ASSAME AS S06352

&nbsp

SPONSORSeawright

&nbsp

COSPNSRStirpe, Lupardo, Buttenschon, Forrest

&nbsp

MLTSPNSR

&nbsp

Amd §6801-a, Ed L; amd §5, Chap 21 of 2011

&nbsp

Includes nurse practitioners as a provider of services for purposes of collaborative drug therapy management; makes the authorization for pharmacists to perform such management permanent.

Go to top A01321 Actions:

BILL NOA01321 

&nbsp

01/09/2025referred to higher education

01/07/2026referred to higher education

Go to topA01321 Committee&nbspVotes:

Go to topA01321 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA01321 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 1321

 2025-2026 Regular Sessions

 IN ASSEMBLY

 January 9, 2025
 ___________

 Introduced by M. of A. SEAWRIGHT, STIRPE, LUPARDO, BUTTENSCHON, FORREST
 -- read once and referred to the Committee on Higher Education

 AN ACT to amend the education law, in relation to including nurse prac-
 titioners as a provider of services for purposes of collaborative drug
 therapy management; and to amend chapter 21 of the laws of 2011 amend-
 ing the education law relating to authorizing pharmacists to perform
 collaborative drug therapy management with physicians in certain
 settings, in relation to making the authorization for pharmacists to
 perform collaborative drug therapy management permanent

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Section 6801-a of the education law, as amended by chapter
 2 238 of the laws of 2015, is amended to read as follows:
 3 § 6801-a. Collaborative drug therapy management [demonstration
 4 program]. 1. As used in this section, the following terms shall have
 5 the following meanings:
 6 a. "Board" shall mean the state board of pharmacy as established by
 7 section sixty-eight hundred four of this article.
 8 b. "Clinical services" shall mean the collection and interpretation of
 9 patient data for the purpose of initiating, modifying and monitoring
 10 drug therapy with associated accountability and responsibility for
 11 outcomes in a direct patient care setting.
 12 c. "Collaborative drug therapy management" shall mean the performance
 13 of clinical services by a pharmacist relating to the review, evaluation
 14 and management of drug therapy to a patient, who is being treated by a
 15 physician or nurse practitioner for a specific disease or associated
 16 disease states, in accordance with a written agreement or protocol with
 17 a voluntarily participating physician or nurse practitioner and in
 18 accordance with the policies, procedures, and protocols of the facility.
 19 Such agreement or protocol as entered into by the physician or nurse
 20 practitioner and a pharmacist, may include, and shall be limited to:

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD02944-01-5

 A. 1321 2

 1 (i) adjusting or managing a drug regimen of a patient, pursuant to a
 2 patient specific order or protocol made by the patient's physician or
 3 nurse practitioner, which may include adjusting drug strength, frequency
 4 of administration or route of administration. Adjusting the drug regimen
 5 shall not include substituting or selecting a different drug which
 6 differs from that initially prescribed by the patient's physician or
 7 nurse practitioner unless such substitution is expressly authorized in
 8 the written order or protocol. The pharmacist shall be required to imme-
 9 diately document in the patient record changes made to the patient's
 10 drug therapy and shall use any reasonable means or method established by
 11 the facility to notify the patient's other treating physicians or nurse
 12 practitioners with whom [he or she] such pharmacist does not have a
 13 written agreement or protocol regarding such changes. The patient's
 14 physician or nurse practitioner may prohibit, by written instruction,
 15 any adjustment or change in the patient's drug regimen by the pharma-
 16 cist;
 17 (ii) evaluating and, only if specifically authorized by the protocol
 18 and only to the extent necessary to discharge the responsibilities